Glaxosmithkline Research & Development Limited

The sponsor has a major portfolio in asthma, including severe eosinophilic asthma, type 2 inflammation, and mild asthma, alongside studies in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. It also funds research in systemic sclerosis-associated interstitial lung disease and other connective tissue disease-associated interstitial lung diseases.

• Severe asthma with eosinophilic phenotype
• COPD and type 2 inflammation
• Idiopathic pulmonary fibrosis
• Interstitial lung disease linked to connective tissue disease

Additional work includes airway mucus and lung-function research in inflammatory respiratory disease, as well as paediatric and adult studies involving inhaled therapy and respiratory infection.

Clinical research also targets systemic lupus erythematosus, systemic sclerosis, atopic dermatitis, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and related immune-mediated conditions. These studies span adult and paediatric populations and include both chronic inflammatory and rare immune disorders.

• Systemic lupus erythematosus
• Atopic dermatitis
• Hypereosinophilic syndrome
• Systemic sclerosis

There is also interest in connective tissue diseases and immune dysregulation affecting the lungs, skin, and blood, with studies addressing long-term disease control and symptom burden.

The sponsor funds research in chronic hepatitis B, including HBV/HIV coinfection, as well as studies in cholestatic pruritus, primary biliary cholangitis, non-alcoholic fatty liver disease, and alcohol-related liver disease. Its portfolio reflects sustained interest in liver-related inflammation, viral persistence, and cholestatic symptoms.

• Chronic hepatitis B
• HBV and HIV coinfection
• Primary biliary cholangitis
• Non-alcoholic fatty liver disease

It also includes antiviral research in influenza and studies involving tuberculosis, broadening its infectious disease activity beyond hepatology.

Glaxosmithkline Research & Development Limited supports clinical studies in early Alzheimer's disease, autosomal dominant polycystic kidney disease, kidney disease, diabetic peripheral neuropathic pain, and knee osteoarthritis pain. These programmes cover neurodegenerative, renal, and chronic pain conditions across adult populations.

• Early Alzheimer’s disease
• Autosomal dominant polycystic kidney disease
• Diabetic peripheral neuropathic pain
• Knee osteoarthritis pain

Its research in this area also includes symptom-focused evaluation in chronic conditions such as pruritus and long-standing inflammatory disease.